Department of Dental Oncology and Maxillofacial Prosthetics, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada.
JCO Oncol Pract. 2020 Nov;16(11):e1397-e1405. doi: 10.1200/OP.20.00107. Epub 2020 Jul 1.
Patients with newly diagnosed acute myeloid leukemia (AML) are at risk of infection, including odontogenic infections, during induction chemotherapy. It is unknown whether clinical dental screening to diagnose and treat odontogenic disease in these patients can reduce the incidence of dental emergencies.
Between November 1, 2014, and December 31, 2016, we screened 147 patients with newly diagnosed AML before their admission for induction chemotherapy (n 147, "screened" group). The patients not screened acted as controls (n = 190, "unscreened" group), as did patients diagnosed with AML in the 26 months before the initiation of the screening program (n = 304, "prescreening" group). The number of patients in each group who presented for emergency dental assessment during admission for induction chemotherapy was determined by 2 independent reviewers.
Among the 147 patients in the screened group, only 1 patient presented with an infectious odontogenic emergency (0.68% [95% CI, -0.64% to 1.98%]). In the unscreened group, 8 developed an infectious odontogenic emergency during induction chemotherapy (4.21% [95% CI, 1.37% to 7.15%]), a statistically significant difference ( = .046, = 0.05). A similar rate of infectious dental emergencies was observed in the prescreening group (4.28% [95% CI, 2.0% to 7.2%]).
Clinical dental screening before induction chemotherapy in patients with AML resulted in a 6-fold reduction in infectious dental emergencies during the induction period.
新发急性髓系白血病(AML)患者在诱导化疗期间有感染风险,包括牙源性感染。目前尚不清楚在这些患者中进行临床牙科筛查以诊断和治疗牙源性疾病是否可以降低牙科急症的发生率。
在 2014 年 11 月 1 日至 2016 年 12 月 31 日期间,我们对 147 例新诊断为 AML 并准备接受诱导化疗的患者进行了筛查(n = 147,“筛查”组)。未进行筛查的患者作为对照组(n = 190,“未筛查”组),筛查前 26 个月诊断为 AML 的患者也作为对照组(n = 304,“预筛查”组)。由 2 名独立评审员确定每组在诱导化疗期间因急诊牙科评估而就诊的患者人数。
在筛查组的 147 例患者中,仅有 1 例出现感染性牙源性急症(0.68%[95%CI,-0.64%至 1.98%])。在未筛查组中,8 例在诱导化疗期间发生感染性牙源性急症(4.21%[95%CI,1.37%至 7.15%]),差异具有统计学意义( =.046, = 0.05)。预筛查组也观察到相似的感染性牙科急症发生率(4.28%[95%CI,2.0%至 7.2%])。
AML 患者在诱导化疗前进行临床牙科筛查可使诱导期内感染性牙科急症的发生率降低 6 倍。